Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has made an important announcement regarding its drug FLT201. The company revealed that FLT201 has been awarded the Innovation Passport for the treatment of Gaucher disease type 1 under the Innovative Licensing and Access Pathway (ILAP) process by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). This milestone represents the first step in the ILAP process, which aims to expedite time to market and enhance patient access to life-threatening or seriously debilitating conditions in the UK.

Following this news, $FRLN is experiencing a significant surge in pre-market trading. Currently valued at $4.07, the stock has increased by $1.08 (+36.12%).

In other updates, Rain Oncology Inc. (Nasdaq: RAIN) announced that the Phase 3 MANTRA trial, which evaluated the efficacy, safety, and tolerability of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS), did not meet its primary endpoint of progression-free survival (PFS) compared to the standard of care, trabectedin, as assessed by blinded independent central review. Based on these topline data, Rain does not plan to pursue further development of milademetan in DD LPS.

$RAIN is currently trading at $9.84 in pre-market, showing a decrease of $0.09 (-0.91%).

Additionally, Chevron Corporation (NYSE: CVX) has entered into a definitive agreement with PDC Energy, Inc. (Nasdaq: PDCE) for the acquisition of all outstanding shares of PDC in an all-stock transaction valued at $6.3 billion, equivalent to $72 per share. This strategic move will bolster Chevron's position in key U.S. production basins, leveraging the attractive and complementary assets of PDC.

During pre-market, $CVX is trading at $154.30, reflecting a decrease of $0.93 (-0.60%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)